semaglutide step 1 : Treatment Effect in People with Obesity – My Endo Consult 🎉 Great news! Tirzepatide EZ

A 2024 study published in JAMA Ophthalmology reported that patients with Type 2 diabetes who took semaglutide-containing medications had more than a fourfold higher risk for developing non-arteritic anterior ischemic optic neuropathy (NAION) compared with patients not on a GLP-1 agonist

[DOI] [PMC free article] [PubMed] [Google Scholar] 2.Nauck MA, Quast DR, Wefers J, Meier JJ

Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: The STEP 4 Randomized Clinical Trial

This observation may explain why semaglutide and other GLP-1 RAs ranked among the lowest-impact DM2 DMTs in our model compared to drugs such as metformin, which engage a broader range of metabolic and neuroprotective pathways (e.g., AMPK, insulin, and adipocytokine signaling)